Table 3.
AE summary in Asian patients with ESCC
| Event, n (%) | Pembrolizumab n = 170 | Chemotherapy n = 166 |
|---|---|---|
| ≥1 AE | 163 (95.9) | 160 (96.4) |
| Grade 3-5 | 85 (50.0) | 102 (61.4) |
| Led to discontinuation | 20 (11.8) | 22 (13.3) |
| Serious | 58 (34.1) | 64 (38.6) |
| Serious and led to discontinuation | 17 (10.0) | 13 (7.8) |
| Led to death | 13 (7.6) | 13 (7.8) |
| ≥1 Treatment-related AE | 122 (71.8) | 149 (89.8) |
| Grade 3-5 | 34 (20.0) | 74 (44.6) |
| Led to discontinuation | 13 (7.6) | 13 (7.8) |
| Serious | 29 (17.1) | 33 (19.9) |
| Serious and led to discontinuation | 10 (5.9) | 5 (3.0) |
| Led to deatha | 3 (1.8) | 2 (1.2) |
AE, adverse event; ESCC, esophageal squamous cell carcinoma.
a
Grade 5 treatment-related AEs were pneumonitis (n = 2) and cardiopulmonary failure (n = 1) in the pembrolizumab group and decreased neutrophil count (n = 1), decreased white blood cell count (n = 1), and pneumonia aspiration (n = 1) in the chemotherapy group.